Liposomal systems are well known for playing an important role as drug carriers, presenting
several therapeutic applications in different sectors, such as in drug delivery, diagnosis, and …

The combination of inflammation and thrombosis is a hallmark of many cardiovascular
diseases. Under such conditions, platelets are recruited to an area of inflammation by …

Cardiovascular diseases (CVDs) are still the first cause of death worldwide. Conventional
small molecular diagnostic and therapeutic agents generally show limited in vivo detection …

Ischemic stroke is one of the major causes of severe disability and death worldwide. It is
mainly caused by a sudden reduction in cerebral blood flow due to obstruction of the …

Acute thrombosis is a leading cause of mortality and morbidity worldwide. Pharmacological
thrombolysis relies on plasminogen activators (PAs), which are associated with major side …

Thrombolysis is a standard treatment for rapidly restoring blood flow. However, the
application of urokinase-type plasminogen activator (Uk) in clinical therapy is limited due to …

Platelets are a significant component of the cell population in the tumour microenvironment
(TME). Platelets influence other immune cells and perform cross-talk with tumour cells …

Biofunctionalization of nanoparticles (NPs) is an essential component in targeted drug
delivery. However, current nanotechnology remains inadequate to imitate complex …

Background Fibrin-rich clot formation in thrombo-occlusive pathologies is currently treated
by systemic administration of plasminogen activators (eg tPA), to convert fibrin-associated …

Thrombosis is a life‐threatening pathological condition in which blood clots form in blood
vessels, obstructing or interfering with blood flow. Thrombolytic agents (TAs) are enzymes …